• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

单独使用阿米卡星和氯法齐明辅助标准方案治疗重度复杂肺部疾病：一项回顾性研究。

Treatment of severe complex pulmonary disease with adjunctive amikacin and clofazimine standard regimen alone: a retrospective study.

作者信息

Zweijpfenning Sanne M H, Kops Stephan E P, Boeree Martin J, Kuipers Saskia, van Ingen Jakko, Hoefsloot Wouter, Magis-Escurra Cecile

机构信息

Dept of Respiratory Diseases, Radboudumc Center for Infectious Diseases, Radboud University Medical Centre Dekkerswald, Nijmegen, The Netherlands.

Co-first authors.

出版信息

ERJ Open Res. 2021 Nov 22;7(4). doi: 10.1183/23120541.00466-2021. eCollection 2021 Oct.

DOI:10.1183/23120541.00466-2021
PMID:34820449
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8607114/
Abstract

https://bit.ly/30dxdRj.

摘要

https://bit.ly/30dxdRj. （此为网址，无法准确翻译为中文，保留原文即可）

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9aeb/8607114/491804307ebf/00466-2021.01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9aeb/8607114/491804307ebf/00466-2021.01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9aeb/8607114/491804307ebf/00466-2021.01.jpg

相似文献

1
Treatment of severe complex pulmonary disease with adjunctive amikacin and clofazimine standard regimen alone: a retrospective study.单独使用阿米卡星和氯法齐明辅助标准方案治疗重度复杂肺部疾病：一项回顾性研究。
ERJ Open Res. 2021 Nov 22;7(4). doi: 10.1183/23120541.00466-2021. eCollection 2021 Oct.
2
A Clofazimine-Containing Regimen Confers Improved Treatment Outcomes in Macrophages and in a Murine Model of Chronic Progressive Pulmonary Infection Caused by the Complex.含氯法齐明的治疗方案在巨噬细胞以及由该复合体引起的慢性进行性肺部感染小鼠模型中可带来更好的治疗效果。
Front Microbiol. 2021 Jan 14;11:626216. doi: 10.3389/fmicb.2020.626216. eCollection 2020.
3
Prescribing Patterns for Treatment of Mycobacterium avium Complex and M. xenopi Pulmonary Disease in Ontario, Canada, 2001-2013.2001-2013 年加拿大安大略省治疗鸟分枝杆菌复合体和胞内分枝杆菌肺部疾病的处方模式。
Emerg Infect Dis. 2019 Jul;25(7):1271-80. doi: 10.3201/eid2507.181817.
4
Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimine.用大环内酯类、乙胺丁醇和氯法齐明治疗鸟分枝杆菌复合群肺病
Chest. 2003 Oct;124(4):1482-6. doi: 10.1378/chest.124.4.1482.
5
Long-term Follow-up of Mycobacterium avium Complex Lung Disease in Patients Treated With Regimens Including Clofazimine and/or Rifampin.使用包含氯法齐明和/或利福平方案治疗的鸟分枝杆菌复合群肺病患者的长期随访
Chest. 2016 May;149(5):1285-93. doi: 10.1378/chest.15-0543. Epub 2016 Jan 12.
6
Activities of roxithromycin used alone and in combination with ethambutol, rifampin, amikacin, ofloxacin, and clofazimine against Mycobacterium avium complex.罗红霉素单独及与乙胺丁醇、利福平、阿米卡星、氧氟沙星和氯法齐明联合使用对鸟分枝杆菌复合群的活性。
Antimicrob Agents Chemother. 1994 Jun;38(6):1433-8. doi: 10.1128/AAC.38.6.1433.
7
In vitro activity of aminoglycosides, clofazimine, d-cycloserine and dapsone against 83 Mycobacterium avium complex clinical isolates.氨基糖苷类、氯法齐明、环丝氨酸和氨苯砜对 83 株鸟分枝杆菌复合体临床分离株的体外活性。
J Microbiol Immunol Infect. 2018 Oct;51(5):636-643. doi: 10.1016/j.jmii.2017.05.001. Epub 2017 Jun 28.
8
Outcomes of Inhaled Amikacin and Clofazimine-Containing Regimens for Treatment of Refractory Complex Pulmonary Disease.吸入用阿米卡星和氯法齐明联合方案治疗难治性复杂性肺部疾病的疗效
J Clin Med. 2020 Sep 14;9(9):2968. doi: 10.3390/jcm9092968.
9
Clofazimine Prevents the Regrowth of Mycobacterium abscessus and Mycobacterium avium Type Strains Exposed to Amikacin and Clarithromycin.氯法齐明可预防暴露于阿米卡星和克拉霉素的脓肿分枝杆菌和鸟分枝杆菌标准菌株的再生长。
Antimicrob Agents Chemother. 2015 Dec 7;60(2):1097-105. doi: 10.1128/AAC.02615-15. Print 2016 Feb.
10
Treatment Outcomes of Clofazimine-Containing Regimens in Severe Complex Pulmonary Disease.含氯法齐明方案治疗重症复杂肺部疾病的疗效
Open Forum Infect Dis. 2023 Dec 28;11(2):ofad682. doi: 10.1093/ofid/ofad682. eCollection 2024 Feb.

引用本文的文献

1
Risk factors, molecular analysis and treatment outcomes of amikacin-resistant complex pulmonary disease.耐阿米卡星复杂性肺部疾病的危险因素、分子分析及治疗结果
ERJ Open Res. 2025 Aug 11;11(4). doi: 10.1183/23120541.01084-2024. eCollection 2025 Jul.
2
Growing from common ground: nontuberculous mycobacteria and bronchiectasis.从共同基础发展而来：非结核分枝杆菌与支气管扩张症。
Eur Respir Rev. 2024 Jul 3;33(173). doi: 10.1183/16000617.0058-2024. Print 2024 Jul.
3
Why do we use 100 mg of clofazimine in TB and NTM treatment?为什么我们在结核病和非结核分枝杆菌治疗中使用 100 毫克氯法齐明？

本文引用的文献

1
Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline.非结核分枝杆菌肺病的治疗：美国胸科学会/欧洲呼吸学会/欧洲临床微生物学与感染病学会/美国感染病学会官方临床实践指南
Eur Respir J. 2020 Jul 7;56(1). doi: 10.1183/13993003.00535-2020. Print 2020 Jul.
2
Non-tuberculous mycobacterial pulmonary disease.非结核分枝杆菌肺病。
Eur Respir J. 2019 Jul 11;54(1). doi: 10.1183/13993003.00250-2019. Print 2019 Jul.
3
A definition of the Mycobacterium avium complex for taxonomical and clinical purposes, a review.
J Antimicrob Chemother. 2024 Apr 2;79(4):697-702. doi: 10.1093/jac/dkae041.
4
Drugs for treating infections caused by non-tubercular mycobacteria: a narrative review from the study group on mycobacteria of the Italian Society of Infectious Diseases and Tropical Medicine.治疗非结核分枝杆菌感染的药物：来自意大利传染病和热带医学学会分枝杆菌研究组的叙述性综述。
Infection. 2024 Jun;52(3):737-765. doi: 10.1007/s15010-024-02183-3. Epub 2024 Feb 8.
5
Real-world treatment patterns in patients with nontuberculous mycobacterial lung disease in the Netherlands based on medication dispensing data.基于药物配给数据的荷兰非结核分枝杆菌肺病患者的真实世界治疗模式。
BMC Pulm Med. 2023 Jun 20;23(1):218. doi: 10.1186/s12890-023-02460-1.
6
Variability of Complex Isolates Drug Susceptibility Testing by Broth Microdilution.采用肉汤微量稀释法对复杂分离株进行药敏试验的变异性
Antibiotics (Basel). 2022 Dec 4;11(12):1756. doi: 10.3390/antibiotics11121756.
7
Clinical Outcome with Standard Regimen plus Clofazimine or Moxifloxacin in Cavitary Mycobacterium avium Complex Pulmonary Disease.标准方案联合氯法齐明或莫西沙星治疗空洞性分枝杆菌肺病的临床结局。
Antimicrob Agents Chemother. 2022 Dec 20;66(12):e0052822. doi: 10.1128/aac.00528-22. Epub 2022 Nov 3.
8
European Respiratory Society International Congress, Madrid, 2019: nontuberculous mycobacterial pulmonary disease highlights.2019年欧洲呼吸学会国际大会，马德里：非结核分枝杆菌肺病亮点
ERJ Open Res. 2020 Oct 19;6(4). doi: 10.1183/23120541.00317-2020. eCollection 2020 Oct.
用于分类学和临床目的的鸟分枝杆菌复合体定义综述
Int J Syst Evol Microbiol. 2018 Nov;68(11):3666-3677. doi: 10.1099/ijsem.0.003026. Epub 2018 Sep 19.
4
Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Complex (CONVERT). A Prospective, Open-Label, Randomized Study.卷曲霉素脂质体吸入混悬液治疗复杂（CONVERT）引起的治疗抵抗性肺病。一项前瞻性、开放标签、随机研究。
Am J Respir Crit Care Med. 2018 Dec 15;198(12):1559-1569. doi: 10.1164/rccm.201807-1318OC.
5
Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement.非结核分枝杆菌肺病的治疗结局定义：一份非结核分枝杆菌网络共识声明
Eur Respir J. 2018 Mar 22;51(3). doi: 10.1183/13993003.00170-2018. Print 2018 Mar.
6
Outcomes of complex lung disease based on clinical phenotype.基于临床表型的复杂肺部疾病的结局。
Eur Respir J. 2017 Sep 27;50(3). doi: 10.1183/13993003.02503-2016. Print 2017 Sep.
7
Treatment and outcome of non-tuberculous mycobacterial pulmonary disease in a predominantly fibro-cavitary disease cohort.以纤维空洞性疾病为主的非结核分枝杆菌肺病的治疗和转归。
Respir Med. 2017 Oct;131:220-224. doi: 10.1016/j.rmed.2017.08.031. Epub 2017 Sep 1.
8
Clofazimine Prevents the Regrowth of Mycobacterium abscessus and Mycobacterium avium Type Strains Exposed to Amikacin and Clarithromycin.氯法齐明可预防暴露于阿米卡星和克拉霉素的脓肿分枝杆菌和鸟分枝杆菌标准菌株的再生长。
Antimicrob Agents Chemother. 2015 Dec 7;60(2):1097-105. doi: 10.1128/AAC.02615-15. Print 2016 Feb.
9
Long-term Follow-up of Mycobacterium avium Complex Lung Disease in Patients Treated With Regimens Including Clofazimine and/or Rifampin.使用包含氯法齐明和/或利福平方案治疗的鸟分枝杆菌复合群肺病患者的长期随访
Chest. 2016 May;149(5):1285-93. doi: 10.1378/chest.15-0543. Epub 2016 Jan 12.
10
Macrolide/Azalide therapy for nodular/bronchiectatic mycobacterium avium complex lung disease.大环内酯类/氮杂内酯类药物治疗结节性/支气管扩张型鸟分枝杆菌复合群肺病。
Chest. 2014 Aug;146(2):276-282. doi: 10.1378/chest.13-2538.